Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs.
The provision of safe, effective, cost-efficient perioperative inpatient acute pain management is an important concern among clinicians and administrators within healthcare institutions. Overreliance on opioid monotherapy in this setting continues to present health risks for patients and increase healthcare costs resulting from preventable adverse events. The goal of this study was to model length of stay (LOS), potential opioid-related complications, and costs for patients reducing opioid use and adding intravenous acetaminophen (IV APAP) for management of postoperative pain.



Data for this study were de-identified inpatient encounters from The Advisory Board Company across 297 hospitals from 2012-2014, containing 2,238,433 encounters (IV APAP used in 12.1%). Encounters for adults ≥18 years of age admitted for cardiovascular, colorectal, general, obstetrics and gynecology, orthopedics, or spine surgery were included. The effects of reducing opioids and adding IV APAP were estimated using hierarchical statistical models. Costs were estimated by multiplying modeled reductions in LOS or complication rates by observed average volumes for medium-sized facilities, and by average cost per day or per complication (LOS: US$2383/day; complications: derived from observed charges).



Across all surgery types, LOS showed an average reduction of 18.5% (10.7-32.0%) for the modeled scenario of reducing opioids by one level (high to medium, medium to low, or low to none) and adding IV APAP, with an associated total LOS-related cost savings of $4.5 M. Modeled opioid-related complication rates showed similar improvements, averaging a reduction of 28.7% (5.4-44.0%) with associated cost savings of $0.2 M. In aggregate, costs decreased by an estimated $4.7 M for a medium-sized hospital. The study design demonstrates associations only and cannot establish causal relationships. The cost impact of LOS is modeled based on observed data.



This investigation indicates that reducing opioid use and including IV APAP for postoperative pain management has the potential to decrease LOS, opioid-related complication rates, and costs from a hospital perspective.



Mallinckrodt Pharmaceuticals.
The Advisory Board Company, Washington, DC, USA.
E Eve
EE
Shaffer
Mallinckrodt Pharmaceuticals, Hampton, NJ, USA. an.pham@mallinckrodt.com.
An
A
Pham
The Advisory Board Company, Washington, DC, USA.
Robert L
RL
Woldman
The Advisory Board Company, Washington, DC, USA.
Andrew
A
Spiegelman
Optum Hospice Pharmacy Services, St Louis, MO, USA.
Scott A
SA
Strassels
Mallinckrodt Pharmaceuticals, Hampton, NJ, USA.
George J
GJ
Wan
, Bernardsville, NJ, USA.
Thomas
T
Zimmerman
D000082:Acetaminophen / Q000191:economics* / Q000627:therapeutic use*; D061605:Administration, Intravenous; D000328:Adult; D017046:Cost Savings / Q000706:statistics & numerical data; D017048:Health Care Costs / Q000706:statistics & numerical data; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data*; D007902:Length of Stay / Q000191:economics* / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy*; D014481:United States
D000082:Acetaminophen
Cost; IV APAP; Intravenous acetaminophen; Length of stay; ORADE; Opioid; Opioid-related adverse drug events; Pain; Pharmacoeconomic; Postoperative